Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients

Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient gr...

Full description

Bibliographic Details
Main Authors: Michael Koziolek, Gerhard A. Mueller, Gry H. Dihazi, Klaus Jung, Constanze Altubar, Manuel Wallbach, Ivana Markovic, Dirk Raddatz, Olaf Jahn, Hülya Karaköse, Christof Lenz, Henning Urlaub, Abdelhi Dihazi, Abdellatif El Meziane, Hassan Dihazi
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/3/639
id doaj-c17fa500a0e64e1e8d81a9df471ac899
record_format Article
spelling doaj-c17fa500a0e64e1e8d81a9df471ac8992020-11-25T02:16:10ZengMDPI AGJournal of Clinical Medicine2077-03832020-02-019363910.3390/jcm9030639jcm9030639Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic PatientsMichael Koziolek0Gerhard A. Mueller1Gry H. Dihazi2Klaus Jung3Constanze Altubar4Manuel Wallbach5Ivana Markovic6Dirk Raddatz7Olaf Jahn8Hülya Karaköse9Christof Lenz10Henning Urlaub11Abdelhi Dihazi12Abdellatif El Meziane13Hassan Dihazi14Clinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Animal Breeding and Genetics, University of Veterinary Medicine Hannover, 30559 Hannover, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Göttingen, 37075 Göttingen, GermanyProteomics Group, Max-Planck-Institute of Experimental Medicine, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyLaboratory of Biotechnology and Molecular Bioengineering, Faculty of Sciences and Techniques Gueliz, Cadi Ayyad University, Marrakech 40000, MoroccoLaboratory of Biotechnology and Molecular Bioengineering, Faculty of Sciences and Techniques Gueliz, Cadi Ayyad University, Marrakech 40000, MoroccoClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyDiabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient groups: diabetes without nephropathy, diabetes with microalbuminuria, diabetes with macroalbuminuria and proteinuria without diabetes. For the longitudinal validation, we recruited 563 diabetic patients and collected 1363 urine samples with the clinical data during a follow-up of 6 years. Comparative urinary proteomics identified four proteins Apolipoprotein A-I (APOA1), Beta-2-microglobulin (B2M), E-cadherin (CDH1) and Lithostathine-1-alpha (REG1A), which differentiated with high statistical strength (<i>p</i> &lt; 0.05) between DN patients and the other groups. Label-free mass spectrometric quantification of the candidates confirmed the discriminatory value of E-cadherin and Lithostathine-1-alpha (<i>p</i> &lt; 0.05). Immunological validation highlighted E-cadherin as the only marker able to differentiate significantly between the different DN stages with an area under the curve (AUC) of 0.85 (95%-CI: [0.72, 0.97]). The analysis of the samples from the longitudinal study confirmed the prognostic value of E-cadherin, the critical increase in urinary E-cadherin level was measured 20 &#177; 12.5 months before the onset of microalbuminuria and correlated significantly (<i>p</i> &lt; 0.05) with the glomerular filtration rate measured by estimated glomerular filtration rate (eGFR).https://www.mdpi.com/2077-0383/9/3/639diabetic nephropathyearly diagnosis/prognosise-cadherinearly biomarker
collection DOAJ
language English
format Article
sources DOAJ
author Michael Koziolek
Gerhard A. Mueller
Gry H. Dihazi
Klaus Jung
Constanze Altubar
Manuel Wallbach
Ivana Markovic
Dirk Raddatz
Olaf Jahn
Hülya Karaköse
Christof Lenz
Henning Urlaub
Abdelhi Dihazi
Abdellatif El Meziane
Hassan Dihazi
spellingShingle Michael Koziolek
Gerhard A. Mueller
Gry H. Dihazi
Klaus Jung
Constanze Altubar
Manuel Wallbach
Ivana Markovic
Dirk Raddatz
Olaf Jahn
Hülya Karaköse
Christof Lenz
Henning Urlaub
Abdelhi Dihazi
Abdellatif El Meziane
Hassan Dihazi
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
Journal of Clinical Medicine
diabetic nephropathy
early diagnosis/prognosis
e-cadherin
early biomarker
author_facet Michael Koziolek
Gerhard A. Mueller
Gry H. Dihazi
Klaus Jung
Constanze Altubar
Manuel Wallbach
Ivana Markovic
Dirk Raddatz
Olaf Jahn
Hülya Karaköse
Christof Lenz
Henning Urlaub
Abdelhi Dihazi
Abdellatif El Meziane
Hassan Dihazi
author_sort Michael Koziolek
title Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
title_short Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
title_full Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
title_fullStr Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
title_full_unstemmed Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
title_sort urine e-cadherin: a marker for early detection of kidney injury in diabetic patients
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2020-02-01
description Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient groups: diabetes without nephropathy, diabetes with microalbuminuria, diabetes with macroalbuminuria and proteinuria without diabetes. For the longitudinal validation, we recruited 563 diabetic patients and collected 1363 urine samples with the clinical data during a follow-up of 6 years. Comparative urinary proteomics identified four proteins Apolipoprotein A-I (APOA1), Beta-2-microglobulin (B2M), E-cadherin (CDH1) and Lithostathine-1-alpha (REG1A), which differentiated with high statistical strength (<i>p</i> &lt; 0.05) between DN patients and the other groups. Label-free mass spectrometric quantification of the candidates confirmed the discriminatory value of E-cadherin and Lithostathine-1-alpha (<i>p</i> &lt; 0.05). Immunological validation highlighted E-cadherin as the only marker able to differentiate significantly between the different DN stages with an area under the curve (AUC) of 0.85 (95%-CI: [0.72, 0.97]). The analysis of the samples from the longitudinal study confirmed the prognostic value of E-cadherin, the critical increase in urinary E-cadherin level was measured 20 &#177; 12.5 months before the onset of microalbuminuria and correlated significantly (<i>p</i> &lt; 0.05) with the glomerular filtration rate measured by estimated glomerular filtration rate (eGFR).
topic diabetic nephropathy
early diagnosis/prognosis
e-cadherin
early biomarker
url https://www.mdpi.com/2077-0383/9/3/639
work_keys_str_mv AT michaelkoziolek urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT gerhardamueller urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT gryhdihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT klausjung urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT constanzealtubar urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT manuelwallbach urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT ivanamarkovic urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT dirkraddatz urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT olafjahn urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT hulyakarakose urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT christoflenz urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT henningurlaub urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT abdelhidihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT abdellatifelmeziane urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
AT hassandihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients
_version_ 1724892240258531328